AtriCure, Inc. (ATRC)
- Previous Close
22.47 - Open
22.85 - Bid 21.86 x 100
- Ask 21.92 x 200
- Day's Range
21.83 - 23.21 - 52 Week Range
20.19 - 59.61 - Volume
599,799 - Avg. Volume
811,696 - Market Cap (intraday)
1.059B - Beta (5Y Monthly) 1.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.80 - Earnings Date Jul 23, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.00
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
www.atricure.com1,200
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: ATRC
Performance Overview: ATRC
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATRC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATRC
Valuation Measures
Market Cap
1.09B
Enterprise Value
1.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.52
Price/Book (mrq)
2.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.98%
Return on Assets (ttm)
-3.86%
Return on Equity (ttm)
-8.17%
Revenue (ttm)
414.6M
Net Income Avi to Common (ttm)
-37.23M
Diluted EPS (ttm)
-0.80
Balance Sheet and Cash Flow
Total Cash (mrq)
105.96M
Total Debt/Equity (mrq)
16.52%
Levered Free Cash Flow (ttm)
-16.06M
Research Analysis: ATRC
Company Insights: ATRC
ATRC does not have Company Insights